ANF Care, the consumer wellness brand of Spain-based Amino Frequency Corporation S.L., announced on July 17 that it plans to introduce its BioCoherence frequency-coded wearable discs to the United States during 2026. The battery-free adhesive products are intended for general wellness rather than for diagnosing or treating disease, while the company says they are designed to support experiences such as rest, calm and renewed energy. It was reported that the products will arrive in the country this year, although a precise launch date, United States pricing and distribution arrangements were not disclosed.
The planned expansion takes technology associated with ANF’s practitioner-led frequency therapy model into the direct consumer wellness market. That is an important commercial shift. A product that previously depended on trained practitioners selecting and positioning discs can potentially reach a much larger audience when packaged around simpler consumer routines, but the change also places greater weight on clear instructions, disciplined marketing and product-specific evidence.
ANF Care describes BioCoherence as a framework centred on the synchronisation of biological rhythms and frequency patterns. The company’s central proposition is that consumers can wear small coded discs on the skin without ingesting substances, receiving electrical stimulation, charging a device or sharing health data. The commercial opportunity rests on that simplicity, while the central evidence question is whether consumers can distinguish a reproducible product effect from expectations, normal day-to-day variation and the influence of other wellness habits.
What is ANF Care actually bringing into the United States consumer wellness market?
ANF Care’s products differ substantially from the smartwatches, rings and connected patches that dominate the wearable technology conversation. Those devices typically collect information such as movement, heart rate, skin temperature or sleep duration and convert it into feedback. ANF Care’s discs contain no batteries or electronics, do not record biometric information and do not connect to an application.
The company instead positions them as passive wellness products. According to ANF Care’s consumer guidance, the BioCoherence Amplifiers are applied to clean, dry skin and may be worn continuously for up to 72 hours. The disclosed consumer portfolio is organised around six areas named Neuro, Physical, Recovery, Energy, Resilience and Longevity.
This makes the products commercially closer to consumable wellness patches than to conventional digital health hardware. The distinction matters because ANF Care will not be competing primarily on sensor accuracy, software functionality or interoperability. It will compete on perceived experience, ease of use, brand credibility, repeat purchasing and the strength of the explanation supporting its frequency-coded technology.
The absence of charging, subscriptions to data platforms and complicated onboarding could lower adoption friction. It also removes the objective feedback loop that helps consumers assess many connected wearables. ANF Care users may therefore judge value through subjective changes in rest, calmness, energy or general well-being, outcomes that are vulnerable to expectation effects and can fluctuate for numerous unrelated reasons.
The company’s European online shop already illustrates the potential breadth of its commercial model. It lists multiple wearable products across areas including respiratory support, focus, digestive wellness, vitality and immune support, with euro-denominated prices ranging from lower-cost individual packs to more expensive multi-disc programmes. However, those listings do not establish which products will form the United States portfolio, what they will cost in dollars or whether the American launch will use the same packaging and claims.
How different is the consumer launch from ANF Therapy’s practitioner-led clinical model?
ANF Care has grown out of the broader work of ANF Therapy and ANF Academy, which train healthcare practitioners to select combinations of discs and place them according to individual assessments. The professional model involves more than handing a patient a standard wearable. Practitioners receive training, assess the person, design a protocol, apply multiple devices and evaluate the response.
The consumer proposition simplifies that process. ANF Care’s guidance describes products selected according to personal wellness interests and applied using the placement guide supplied with each pack. That structure may make direct online sales and broader distribution possible, but it also means evidence generated through customised, practitioner-administered ANF Therapy cannot automatically be treated as validation of every self-applied consumer product.
This is one of the most important distinctions surrounding the United States launch. A trained therapist may use several discs, vary their placement and assess a patient within a broader clinical interaction. A consumer purchasing a standard pack is engaging with a different delivery model, even if the underlying technology is related.
ANF Care will consequently need consistency across manufacturing, coding, adhesive performance, placement instructions and product labelling. If a product’s proposed effect depends on a particular disc combination or anatomical placement, usability testing becomes relevant. A simple wearable can lose much of its simplicity if consumers struggle to select the appropriate pack, apply it correctly or interpret what they experience.
What does the available ANF Therapy study show, and where does its evidence stop?
The most substantial published clinical evidence associated with ANF is a 2023 real-world observational study involving 1,054 adults with pain complaints treated by 113 therapists across 45 countries. The Journal of Physical Therapy Science study reported that average pain scores declined from 7.6 before treatment to 3.1 following an ANF Therapy session. Patient and clinician satisfaction was also high.
Those results provide a signal that merits further investigation, particularly because the dataset was large, international and collected across numerous clinics. The study also attempted to document tolerability rather than presenting the intervention as entirely free of unwanted effects. Mild effects were reported by 42.3% of participants, most commonly dry mouth, headache and fatigue. No severe events were reported within the disclosed observation period.
However, the design does not establish that ANF discs caused the reported pain reduction. It was a single-arm observational study without randomisation, a sham intervention or a control group. Outcomes were measured before and between 10 and 60 minutes after one session, leaving long-term durability unknown. Pain was self-reported, while changes in swelling and range of motion were assessed using non-standardised clinician observations.
The investigators acknowledged that placebo and other undetected biases could have influenced the findings. They recommended a randomised, sham-controlled study with blinded assessment and longitudinal follow-up. One author worked for ANF Academy, while another had received scientific consulting fees from the organisation. Those relationships do not invalidate the results, but they reinforce the value of independent replication.
The evidence gap becomes wider when moving from ANF Therapy to ANF Care. The study evaluated patients receiving individually designed protocols from trained practitioners, not consumers independently using standard BioCoherence products for general wellness. It focused primarily on pain, with sleep and relaxation recorded as unexpected observations among some participants. It was not designed to establish benefits involving calmness, renewed energy, cognitive performance or longevity.
For the United States launch, product-specific studies would therefore be more informative than relying on the broader ANF Therapy dataset. A credible programme could compare active and visually identical sham discs, prespecify the claimed wellness outcome, use validated measurement instruments and follow participants for long enough to determine whether any effect persists.
Why does general wellness positioning define ANF Care’s United States regulatory boundary?
ANF Care’s website states that its consumer products are intended for general wellness and are not designed to diagnose, treat, cure or prevent disease. That positioning is commercially significant because regulatory treatment in the United States depends heavily on intended use and the claims communicated through labels, websites, advertising, affiliates and social media.
The United States Food and Drug Administration’s January 2026 guidance addresses low-risk products that promote a healthy lifestyle without making claims connected to diagnosing, curing, mitigating, preventing or treating a disease. A passive product marketed around general well-being may therefore occupy a different regulatory category from a device promoted as treating chronic pain, anxiety, insomnia, inflammation or another medical condition.
ANF Care’s launch announcement did not identify a 510(k) clearance, De Novo authorisation, Premarket Approval application or cleared medical indication for the consumer discs. It should consequently be understood as a wellness product launch, not as the commercialisation of a treatment cleared or approved for a disease.
That distinction must also be maintained when discussing FDA registration. Professional ANF materials have referred to FDA registration for related Class I devices, but registration and product listing do not demonstrate efficacy or represent marketing approval. The United States Food and Drug Administration explains that an entry in its registration and listing database does not denote approval, clearance or authorisation of a facility or its medical devices.
Advertising is another part of the regulatory equation. The Federal Trade Commission expects health-related claims to be supported by competent and reliable scientific evidence. Its health products compliance guidance identifies controlled human clinical testing as particularly important when a company claims that a product produces a health benefit.
ANF Care will therefore need to ensure that distributors, influencers and affiliates remain within the intended general wellness boundary. Claims can travel quickly in the biohacking market, and enthusiastic testimonials may drift from subjective wellness experiences into statements about treating medical conditions. Consistent marketing oversight will be as important as the language printed on the product packaging.
Can a passive wearable without sensors build a defensible position in consumer health?
The lack of electronics gives ANF Care several potential commercial advantages. The products are small, discreet and free from charging requirements, software updates and health-data privacy concerns. They may appeal to consumers who dislike swallowing supplements or do not want another connected device monitoring their behaviour.
The consumable format also creates the possibility of repeat purchases. If each disc is worn for up to 72 hours, continued use requires replacement products rather than a one-time hardware sale. That can support recurring revenue, particularly if ANF Care develops subscription bundles around sleep, recovery, energy or resilience.
Yet the same format creates a demanding customer-retention test. Consumers must perceive enough value to keep buying a product that does not generate a score, graph or measurable feedback report. Without stronger independent evidence, marketing, testimonials and personal expectation could play an unusually large role in purchase decisions.
The United States wellness market is large, but it is also noisy. ANF Care will compete for attention with supplements, adhesive wellness patches, meditation applications, sleep products, recovery tools and conventional wearables. Being unusual may help the brand win initial curiosity. Building a durable business will require the company to convert that curiosity into repeat use without allowing promotional language to move beyond the available evidence.
Which milestones will reveal whether ANF Care can build a durable United States business?
The first test will be operational clarity. ANF Care has announced that its technology is coming to the United States during 2026, but it has not publicly detailed the exact launch date, American product range, dollar pricing, local fulfilment arrangements, retail partners or expected availability. Those details will determine whether the announcement becomes a broad commercial rollout or a limited direct-to-consumer introduction.
The second test will be evidence generation. A randomised, sham-controlled study of the actual consumer products would provide substantially more useful information than another uncontrolled satisfaction survey. Outcomes should correspond directly with the claims used in the United States, whether those involve perceived rest, calmness, energy or another general wellness measure.
Post-market monitoring will also matter. Adhesive-related redness, itching, discontinuation rates, product returns and complaints should be tracked systematically. Repeat purchase rates would provide a commercial signal, but they should not be confused with clinical validation.
ANF Care has selected an intriguing market proposition: a wearable that does not measure the body, introduce an ingredient or require a power source. Its simplicity could distinguish it in an increasingly complicated wearable market. The decisive question is whether the company can support that simplicity with disciplined claims, reproducible manufacturing, credible product-specific research and a clearly executed United States launch.
